Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod
01:53pm, Thursday, 08'th Jun 2023
Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.
Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)
07:20pm, Wednesday, 07'th Jun 2023
A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
11:59am, Tuesday, 06'th Jun 2023
Biogen BIIB announced that it is discontinuing one of the two studies on its and partner Denali Therapeutics' DNLI small molecule LRRK2 inhibitor, BIIB122, for Parkinson's disease.
Medicare unveils plan for coverage of new Alzheimer's drugs
01:44pm, Thursday, 01'st Jun 2023
Medicare on Thursday announced plans for coverage of new Alzheimer's drugs whose accessibility has become a point of controversy.
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
12:17pm, Thursday, 01'st Jun 2023
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?
12:32pm, Thursday, 25'th May 2023
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
10:00am, Friday, 19'th May 2023
The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
08:15am, Friday, 19'th May 2023
Biogen and Eli Lilly both have promising Alzheimer's drugs that have shown they are effective in slowing the rate of cognitive decline in patients. They both come with risks related to brain swelling
Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on
07:27pm, Monday, 15'th May 2023
CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty.
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
08:15am, Sunday, 14'th May 2023
Two new medicines are going to compete for the Alzheimer's therapy market. Eli Lilly's candidate appears to be more effective, but it isn't approved yet.
3 Reasons to Buy Biogen Stock (and 1 to Sell)
10:15am, Friday, 12'th May 2023
Biogen has been struggling in recent years, but a couple of new products could help bolster its top line. The stock trades at a discount, which may be an opportunity, especially given the potential fo
Biogen Stock Hits Fresh High on Eli Lilly Buzz
10:59am, Wednesday, 03'rd May 2023
The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug donanemab.
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
09:16am, Wednesday, 03'rd May 2023
Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline. The post Eli Lilly Surges After Alzheimer's Treatment Succeeds; B
Biogen prices new ALS treatment at $14,230 per vial
12:14pm, Tuesday, 02'nd May 2023
Biogen Inc. BIIB has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerat
Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease
09:00am, Sunday, 30'th Apr 2023
Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
